Saxena Nishant C 4

4 · Corbus Pharmaceuticals Holdings, Inc. · Filed May 22, 2026

AI-generated summary of this filing

Updated May 22, 2026

Corbus Pharmaceuticals (CRBP) CBO Nishant Saxena Receives Award

What Happened

Nishant C. Saxena, Chief Business Officer of Corbus Pharmaceuticals (CRBP), received equity awards on May 21, 2026: 58,300 restricted stock units (RSUs) and a 192,300-share derivative award (total 250,600 units). Both awards were granted at a $0.00 purchase price (typical for compensation grants) and are unvested at grant.

Key Details

Transaction date: May 21, 2026 (Form 4 filed May 22, 2026 — timely filing).
Awards: 58,300 RSUs (settled in common stock) + 192,300 derivative award (reported as a derivative grant).
Price: $0.00 per share (grant price = $0 at issuance); total intrinsic cash paid = $0.
Vesting (RSUs): 25% vest on each of the first four anniversaries beginning May 21, 2027. RSUs include a partial acceleration provision if the Company terminates Saxena without cause after the first vesting date (prorated acceleration toward next vesting); unvested RSUs are otherwise forfeited on termination.
Vesting (derivative/option): Annual option award per the 2024 Equity Compensation Plan. 25% vests May 21, 2027; remaining 75% vests in equal monthly installments over 36 months beginning June 21, 2027.
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing timeliness: Reported on May 22, 2026 for a May 21, 2026 grant — appears timely. No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context

These are compensation grants (code A) and not open-market purchases or sales; such awards are part of executive compensation and do not necessarily indicate a change in personal market view.
The 192,300 derivative award reflects an option/other equity right with a multi-year vesting schedule — the shares are not immediately tradable until vested and, if options, typically require exercise.

Form 4

Period: 2026-05-21

Chief Business Officer

Transactions

Award
Common Stock, par value $0.0001 per share
[F1][F2]
2026-05-21+58,300→ 61,800 total
Award
Stock options (right to buy)
[F3]
2026-05-21+192,300→ 192,300 total
Exercise: $11.51Exp: 2036-05-21→ Common Stock (192,300 underlying)

Footnotes (3)

[F1]On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.
[F2]This amount includes 58,300 unvested RSUs granted on May 21, 2026.
[F3]The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027.

Signature

/s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena|2026-05-22

1 file